Strides Shasun in a BSE filing today announced receiving an approval from the US health regulator for Ranitidine tablets used for treating intestinal and stomach ulcers and gastroesophageal reflux disease.
"We have received approval from the US Food and Drug Administration (USFDA) for Ranitidine tablets USP, 150 mg and 300 mg," said Shasun in the filing.
The company will manufacture the product at its Cuddalore and Pondicherry facilities.
According to IMS sales data, the US market for Ranitidine tablets USP, 150 mg and 300 mg is around USD 125 million.
Disclaimer: No Business Standard Journalist was involved in creation of this content
